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Human “Nuclear” Mitochondrial Cardiomyopathy
A Novel Mouse Model Characterizes the Disease*
Eloisa Arbustini, MD, Maurizia Grasso, PHD
Pavia, ItalyMitochondrial Cardiomyopathies
Can Result From Defects of Nuclear
and Mitochondrial Genes
Mitochondria generate much of the energy for the
cell by oxidative phosphorylation (1); accordingly,
mitochondrial diseases preferentially affect tissues
with high energy demands, such as the heart, brain,
muscle, and endocrine system. The heart is affected
either as an isolated organ (cardiomyopathies) or,
more frequently, as one of the organs/tissues
See page 1
involved in more complex systemic disorders/
syndromes (including encephalomyopathies and
chronic ophthalmoplegia with myopathy). Cardio-
myopathy can represent the initial presentation of
mitochondrial diseases (2). Because proteins con-
tributing to energy production are encoded by both
mitochondrial and nuclear genes, mitochondrial
diseases can be inherited both as matrilineal (mito-
chondrial deoxyribonucleic acid [mtDNA] genes)
and Mendelian (nuclear genes) traits (3).
mtDNA-related disorders can result from muta-
tions in protein-encoding genes or in genes encod-
ing transfer ribonucleic acids and ribosomal ribo-
nucleic acids (4). Mendelian mitochondrial diseases
can result from mutations in nuclear genes coding
subunits of the respiratory chain, proteins involved
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
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to disclose.in intergenomic nuclear-mitochondrial cross-talk
(mtDNA maintenance, replication, or translation),
proteins involved in mechanisms of protein assem-
bly and import, synthesis and composition of mi-
tochondrial membrane, and mitochondrial dynam-
ics (5). A complex interplay regulates the functional
integration of products coded by nuclear and mito-
chondrial genes, and several nuclear genes are in-
volved in the control of mtDNA stability. Disorders
of mtDNA maintenance frequently show Mende-
lian inheritance; they are associated with multiple
mtDNA deletions (6) and depletion (7). The clin-
ical impact of defects in mtDNA maintenance has
recently been shown to go beyond rare Mendelian
and matrilineal diseases affecting mitochondrial
biogenesis, and extend to multifactorial common
conditions such as human heart failure (8). There-
fore, models of mitochondrial diseases influencing
the maintenance of mtDNA may provide new in-
sights for investigating mechanisms of heart failure.
Adenine nucleotide translocators (ANT). The ANT
proteins are adenosine diphosphate (ADP)/
adenosine triphosphate (ATP) carriers that belong
to the mitochondrial anion carrier protein family (9)
and transport solutes across the inner mitochondrial
membrane (10). ANT is, in fact, embedded in the
inner mitochondrial membrane and constitutes ap-
proximately 10% of mitochondrial proteins (11).
ANT has a dual function: under physiological
conditions, it catalyzes ADP/ATP exchange across
the inner mitochondrial membrane, whereas under
lethal stimuli, ANT contributes to apoptosis via
opening of the mitochondrial permeability pore
with translocation of pro-apoptotic proteins such as
cytochrome c (9,12).
In its functional homodimeric conformation of
30-kD subunits, ANT forms gated pores through
which the ATP synthesized in the mitochondrial
matrix by oxidative phosphorylation is exported to
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12he cytosol, in exchange for ADP (13). Inside of the
nner mitochondrial membrane, ATP binds to one
f the subunits; outside, ADP binds to the other
ubunit. The electrochemical gradient of the inner
embrane, which is high under physiological con-
itions, drives the 2 adenine nucleotides to opposite
ides of the membrane (13). Recent studies propose
monomeric transport model in which access to a
ingle substrate binding site is controlled by 2
anking salt bridge networks (14).
The human ANT subfamily is composed of 4
ifferentially expressed isoforms, namely ANT1 to
NT4, encoded by 4 nuclear genes, with ANT1 to
NT3 sharing approximately 90% homology at the
mino acid level (15–18). The ANT1 and ANT3
soforms induce mitochondrial apoptosis, whereas
NT2 and ANT4 isoforms render cells resistant to
eath-inducing stimuli (19,20). The human heart-
uscle specific isoform ANT1 is coded by a small
evelopmentally regulated nuclear gene (ANT1; Chr
q35-1ter) that has 4 exons and a promoter with
he typical CCAAT and TATA sequences (15). The
orresponding mouse Ant1 gene maps to chromo-
ome 8, syntenic to human chromosome 4q35, and
as 4 exons (21,22).
he Ant1 cardiomyopathy hypothesis. In this issue of
JACC, Narula et al. (23) have used an experimental
nt1 beta-geo mutant (Ant1/) mouse model (21)
o test the hypothesis that chronic mitochondrial
nergy deficiency causes dilated cardiomyopathy.
maging studies characterize the clinical phenotype of
NT1 cardiomyopathy. Narula et al. (23) performed a
ulti-step in vivo investigation using 2-dimensional
chocardiography with M-mode and velocity vec-
or imaging (VVI) in a large series of mutant
ersus control (Ant1/) mice 2 to 21 months of
ge. The imaging studies aimed at evaluating left
entricular (LV) morphology and function in
utant versus normal mice.
The first step of the study was the comparison of
ll mutant versus control mice. Although the heart
eight and heart/body weight ratio, left ventricular
imension at end diastole and end-systole, inter-
entricular septum (IVS), left ventricular posterior
all thickness, and IVS/posterior wall ratio were
ignificantly increased in mutant mice, the frac-
ional shortening and LV ejection fraction (EF)
ere significantly reduced. The cardiomyopathy
eveloped in the mutant animals was characterized
y early LV concentric hypertrophy and late dila-
ion and dysfunction.
The second step of the study addressed theuestion of variability of contractile parameters in putant mice and the hypothesis that variable pa-
ameters may depend on penetrance or be age-
ependant. The results demonstrated that the EF
f mutant mice declined with age, being signifi-
antly more impaired in older mice (15 months).
utant mice were then grouped according to the
ean EF and SD on a cutoff value of 56%, which
evealed that the EF was below lower normal limits
n nearly 60% of mutant animals. By recalculating
arameters in the 2 subgroups of mutant mice with
ormal and abnormal EF, the latter showed larger
entricles. Mutant mice with normal or abnormal
F also showed significant increase in IVS thick-
ess.
Finally, the evaluation of contractile mechanics
ocumented that both normal EF and abnormal EF
utants showed reduction in LV rotational veloc-
ties, more pronounced in the latter subgroup.
ircumferential strain and radial strain were re-
uced in mutant as compared to control mice, and
he decline was more severe in animals with abnor-
al EF than those with normal EF. These obser-
ations indicate that mutant mice with normal EF
how abnormal subclinical contractile indexes. Mu-
ant mice also showed significantly decreased LV
pical rotation. The LV apical rotation and twist are
ignificantly influenced by LV configuration
24,25). Interestingly, circumferential strain, radial
train, and rotational velocity in diastole showed
etter accuracy than EF in differentiating mutants
rom control mice and mutant mice with normal
F from control mice.
Overall, the extensive echocardiography studies
howed that Ant1/ mice develop a “hypertro-
hic concentric dilated cardiomyopathy.” This phe-
otypical description, which seems to contain con-
radictory terms, actually reflects the phenotype of
uman mitochondrial cardiomyopathies, both
endelian and matrilineal, which are characterized
y early concentric hypertrophy and later progres-
ion to dilation and dysfunction. In fact, mitochon-
rial cardiomyopathies in their end-stage often look
ike dilated cardiomyopathies (26).
athology studies conﬁrm the clinical phenotype.
utant animals showed myocyte hypertrophy and
nterstitial inflammation, as expected from imaging
tudies; additional findings were myofibrillar lysis,
yocyte calcification, and binucleation. Myocyte
ypertrophy was significantly more common in
oung mutants (12 months old), and this differ-
nce in myocyte hypertrophy was lost in older mice,
ue to the increased presence of myocyte hypertro-
hy in older control mice. The increased myocyte
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13ize in mitochondrial cardiomyopathies is typically
ue to mitochondrial proliferation (21), and is a
allmark of mitochondrial cardiomyopathies. Fi-
rosis was also increased in mutant hearts, and was
ven more evident and significant in older mutants,
hich also showed replacement fibrosis. Therefore,
ypertrophy is an early finding, concordant with
unctional and morphologic data in vivo, whereas
brosis appears later and occurs with greater fre-
uency in mutants.
nt1/ hearts and activation of apoptosis pathway.
he Western blot analysis showed 6-fold higher
ytochrome c levels, 4-fold increase of full-length
aspase-3, and a significant proportion of cleaved
aspase-3 in the older mutants as compared with
lder control mice; further, negligible levels of
ctivated caspase 3 were observed in control mice.
NT1 plays a major role in promoting apoptosis.
n fact, it is a component of the mitochondrial
ermeability transition pore (mtPTP) (27) that
ediates the mitochondrial membrane permeabili-
ation, a rate-limiting step of apoptosis. Opening of
tPTP dissipates the electrochemical gradient and
nhibits ATP synthesis; the mitochondrial matrix
wells, and the outer membrane ruptures, with
elease of cytochrome c and other proapoptotic
roteins into the cytosol. Mitochondria from livers
f Ant1/ mice still possess mtPTP activity, as
Figure 1. Human ANT1 Gene and Mutations Reported to Date
The schematic shows the structure of the human ANT1 gene and th
nant Chronic Progressive External Ophthalmoplegia (CPEO) (31–33)
ANT1 gene maps at chromosome 4q35; it has 4 exons, as does the
and contains the highly conserved consensus sequence RRRMMM, w
which the adenine nucleotides bind. The promoter beta-geo casset
mutation causing cardiomyopathy predicts a p.Ala123Asp substituti
athy; HCM  hypertrophic cardiomyopathy.NT is a structural component of mtPTP and
ubstantially contributes to its regulation (28). This
roperty makes the Ant1/ model especially
nteresting to test the effects of molecules modulat-
ng the apoptotic cascade (29).
uman diseases associated with mutations of the
NT1 gene. The number of mutations of ANT1 re-
orted to date in humans is limited (Fig. 1): most ANT1
efects are associated with autosomal dominant Chronic
rogressive External Ophthalmoplegia without cardio-
yopathy (30–32); the sole cardiomyopathy reported in
umans to date is autosomal recessive and is character-
zed by concentric left ventricular hypertrophy, dilation,
nd dysfunction (33), a phenotype that is reproduced by
he Ant1/ mouse model in the present study (23).
he low number of reported cases can be due to the
till-limited screening studies or to the true rarity of
NT1 mutations as cause of cardiomyopathy. The “hy-
ertrophic dilated phenotype” might be clinically con-
ounding, and the recessive inheritance does not help,
specially in small families in which consanguinity might
ot be apparent or there are no markers to guide genetic
esting to ANT1. The Ant1/ mouse model high-
ights the relevance of knowing the entire natural history
f cardiomyopathies or investigating large series to estab-
ish the natural course of the disease. A patient seen in
he early phase of the disease may show concentric LV
ypertrophy without dilation, whereas a patient seen in
utations reported to date in humans that cause autosomal domi-
autosomal recessive cardiomyopathy and myopathy. The human
se Ant1 gene. Each ANT1 monomer has 6 transmembrane helixes
the 3 arginine residues lying at the base of a conical well in
f the Ant1/ mice is inserted into the exon 2; the only ANT1
n exon 2. AA  amino-acid residues; DCM  dilated cardiomyop-e m
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14he late phases of the diseases may show dilation and
ysfunction, and the hypertrophy markers—both elec-
rocardiographic and echocardiographic—may be lost.
nless other family members are diagnosed in their early
hases, the disease can be labeled as dilated cardiomyop-
thy. This late phenotypemight limit the investigation of
onsarcomeric genes that cause hypertrophic cardiomy-
pathy, especially when parental status is unknown.
ranslational impact of the animal model: when should
ardiologists suspect “nuclear” mitochondrial cardio-
yopathies? Human mitochondrial cardiomyopa-
hies, both matrilineal and Mendelian, typically
how progressive evolution though LV dilation and
nd-stage heart failure (26), independent of the
ossible early hypertrophic concentric phenotype.
he Ant1/ model reflects the phenotype and
volution of mitochondrial cardiomyopathies (23).
arely, the heart is the only affected organ/tissue,
specially at onset (2): the “hypertrophic dilated
ardiomyopathy” phenotype recurs in several mito-
hondrial diseases caused by defects of nuclear
enes. Most of them share autosomal recessive
nheritance (Leigh Syndrome [34], Sengers Syn-
rome [35], dilated cardiomyopathy and ataxia
36]) or are X-linked recessive, such as Barth
yndrome (37). The family data and clinical mark-
rs that may guide diagnostic investigation include
he nonmatrilineal inheritance; the involvement of
keletal muscle, brain, eyes, and liver; and the
resence of lactic acidosis either after effort or atActa Neurol Belg 2006;106:66–72. locase: a components far as the number of reported cases increase, thus
roviding a clinical guide for suspecting nuclear
itochondrial cardiomyopathies.
uture considerations. Mitochondrial dysfunction
ccounts for impaired myocardial energetics and
ncreased cell death during myocardial injury and
he development of heart failure. Animal models
eproducing human mitochondrial dysfunction,
oth monogenic cardiomyopathy phenotypes ob-
erved in rare diseases and multifactorial disorders
ssociated with loss of mtDNA, are of extraordinary
mportance to investigate pathogenetic mechanisms
nd explore the effects of existing or novel drugs/
olecules for possible disease-specific treatments,
otentially recovering energy production and inter-
ering with the loss of energy. The Ant-/- mouse
odel, reported by Narula et al. (23), very elegantly
eproduces the clinical phenotype of cardiomyopa-
hies caused by homozygous ANT1 gene defects in
umans and should be potentially useful for devel-
ping novel pharmacologic interventions. Immedi-
te advantages are related to the application of the
est imaging approaches and novel imaging tools,
articularly in the early, subclinical phases of the
isease.
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